Objective:To evaluate the efficacy and safety of 1 064 nm Nd:YAG picosecond laser of dual-mode with auxiliary functional product introduction in treatment of melasma.Methods:A prospective study was conducted from March 2022 to September 2023 at the Department of Cosmetic Dermatology, Guangzhou Zesee Plastic Surgery Hospital, including 46 female patients with melasma, aged 26-53 (38.5±7.0) years. Patients were randomly divided into two groups using a random number table: experimental group (1 064 nm Nd:YAG picosecond laser dual-mode treatment followed by the introduction of functional product) and control group (1 064 nm Nd:YAG picosecond laser of dual-mode treatment followed by the introduction of 0.9% NaCl), with 23 patients in each group. By using the melasma area and severity index (MASI) score, the physician′s global assessment and the patient′s satisfaction evaluation as evaluation indicators, the treatment effects were assessed at different time points. Adverse reactions were recorded in both groups.Results:At 4 and 12 weeks after the third treatment, the MASI scores in the experimental group were lower than those of the control group ( P<0.001). At 4 weeks after the third treatment, the rate of moderate or above improvement in pigment spots was 95.7% (22/23) in the experimental group, which was higher than the 69.6% (16/23) in the control group ( P=0.011). At 12 weeks after the third treatment, the rate of moderate or above improvement in the experimental group was 30.4% (7/23), which was higher than the 8.7% (2/23) in the control group ( P=0.006). At 24 weeks after the third treatment, the rate of moderate or above improvement in the experimental group was 13.0% (3/23), which was higher than the 0% (0/23) in the control group ( P=0.015). At 4 weeks after the third treatment, the satisfactory rate in the experimental group was 73.9% (17/23), which was higher than the 43.5% (10/23) in the control group ( P=0.009). At 12 weeks after the third treatment, the satisfactory rate in the experimental group was 69.6% (16/23), which was higher than the 39.1% (9/23) in the control group ( P=0.040). At 24 weeks after the third treatment, the satisfactory rate in the experimental group was 56.5% (13/23), which was higher than the 4.4% (1/23) in the control group ( P=0.002). One patient in the experimental group experienced mild itching on the cheek on the second day post-treatment. In the control group, two patients experienced mild itching and erythema on the second day post-treatment. No serious adverse reactions, such as blisters, scabs, or pigmentation, were observed in either group during the treatment or follow-up periods. Conclusion:The 1 064 nm Nd:YAG picosecond laser of dual-mode with auxiliary functional product introduction in treatment of melasma has a better efficacy, with a shorter recovery period and fewer adverse reactions.

Objective:To evaluate the efficacy and safety of 1 064 nm Nd:YAG picosecond laser of dual-mode with auxiliary functional product introduction in treatment of melasma.Methods:A prospective study was conducted from March 2022 to September 2023 at the Department of Cosmetic Dermatology, Guangzhou Zesee Plastic Surgery Hospital, including 46 female patients with melasma, aged 26-53 (38.5±7.0) years. Patients were randomly divided into two groups using a random number table: experimental group (1 064 nm Nd:YAG picosecond laser dual-mode treatment followed by the introduction of functional product) and control group (1 064 nm Nd:YAG picosecond laser of dual-mode treatment followed by the introduction of 0.9% NaCl), with 23 patients in each group. By using the melasma area and severity index (MASI) score, the physician′s global assessment and the patient′s satisfaction evaluation as evaluation indicators, the treatment effects were assessed at different time points. Adverse reactions were recorded in both groups.Results:At 4 and 12 weeks after the third treatment, the MASI scores in the experimental group were lower than those of the control group ( P<0.001). At 4 weeks after the third treatment, the rate of moderate or above improvement in pigment spots was 95.7% (22/23) in the experimental group, which was higher than the 69.6% (16/23) in the control group ( P=0.011). At 12 weeks after the third treatment, the rate of moderate or above improvement in the experimental group was 30.4% (7/23), which was higher than the 8.7% (2/23) in the control group ( P=0.006). At 24 weeks after the third treatment, the rate of moderate or above improvement in the experimental group was 13.0% (3/23), which was higher than the 0% (0/23) in the control group ( P=0.015). At 4 weeks after the third treatment, the satisfactory rate in the experimental group was 73.9% (17/23), which was higher than the 43.5% (10/23) in the control group ( P=0.009). At 12 weeks after the third treatment, the satisfactory rate in the experimental group was 69.6% (16/23), which was higher than the 39.1% (9/23) in the control group ( P=0.040). At 24 weeks after the third treatment, the satisfactory rate in the experimental group was 56.5% (13/23), which was higher than the 4.4% (1/23) in the control group ( P=0.002). One patient in the experimental group experienced mild itching on the cheek on the second day post-treatment. In the control group, two patients experienced mild itching and erythema on the second day post-treatment. No serious adverse reactions, such as blisters, scabs, or pigmentation, were observed in either group during the treatment or follow-up periods. Conclusion:The 1 064 nm Nd:YAG picosecond laser of dual-mode with auxiliary functional product introduction in treatment of melasma has a better efficacy, with a shorter recovery period and fewer adverse reactions.